The Filing Desk

Protagonist Therapeutics vs Septerna

Protagonist Therapeutics PTGX · Septerna SEPN · Biotechnology

Protagonist Therapeutics reported revenue of $46 million in fiscal 2025, about the same as Septerna's $46 million in fiscal 2025. Protagonist Therapeutics' revenue fell 89.4% in its latest year, and Septerna's grew 4174.5%. Protagonist Therapeutics had an operating margin of -343.6%, against -148.6% at Septerna. Free cash flow was $56 million at Protagonist Therapeutics and $110 million at Septerna.

Side by side

Protagonist TherapeuticsSepterna
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$46M$46M
Revenue growth−89.4%4,174.5%
Revenue growth a year, last 5 years10.0%—
Gross margin——
Operating margin−343.6%−148.6%
Net margin−282.8%−106.4%
Free cash flow$56M$110M
Free cash flow margin121.9%238.7%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count−2.3%347.5%
Last close$130.95$42.60
P/E at the last close27.8×—
Insider trades, last 12 monthssold $79.4 million—
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Protagonist TherapeuticsSepterna
Operating margin
Percent of revenue
Protagonist TherapeuticsSepterna
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Protagonist TherapeuticsSepterna

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Protagonist Therapeutics and Septerna pages.